MARINA DEL REY, Calif., Sept. 17, 2014 /PRNewswire/ -- Prostate Oncology Specialists announces the launch of the Prostate Vanguard, an awareness campaign to educate men about new imaging technology destined to replace multiple rectal needle biopsies of the prostate. Annually, a million men undergo random needle biopsy of the prostate gland through the rectum. Multi-parametric MRI (MP-MRI) of the prostate gland is non-invasive alternative for diagnosing clinically-significant prostate cancer (CSPC). Men need to be fully informed of their alternatives.
Random needle biopsy is a multibillion dollar industry performed in one-million men annually. Random biopsy is the direct cause of the unfortunate diagnosis of clinically insignificant prostate cancer (CIS-PC) in over 100,000 men annually in the US, leading to rampant overuse of unnecessary radical treatment with surgery or radiation.
Mark Scholz, MD, Medical Director of Prostate Oncology Specialists, Executive Director of the Prostate Cancer Research Institute, and author of Invasion of the Prostate Snatchers, devotes his medical practice exclusively to prostate cancer patients and advocates for raising awareness about the importance of unnecessary biopsies.
Dr. Scholz states, "With new imaging technology, the medical world has the ability to track, measure, and observe small abnormalities in the prostate, which saves men from having to undergo random biopsies which lead to misdiagnosis and overtreatment."
Prostate Cancer Survivor, Steven Schwartz, was given a 14 needle random biopsy after his doctor found a small bump on his prostate. The biopsy failed to find any cancer but there was still no explanation for the bump. Mr. Schwartz consulted Dr. Scholz for a second opinion and underwent a targeted biopsy utilizing only 3 sticks. All three biopsy cores came back positive for prostate cancer. "Because I had a targeted biopsy, I was saved from overtreatment and was able to have a less invasive process. I am extremely happy with the results."